The aim of the present articleis to reviews the published data on the influence of pharmacogeneticson drug treatment of epilepsy and to present the results fromR.Macedonia in this area. For this article, we reviewed the Englishliterature listed on PubMed published during the last 20 years usingthe following keywords: antiepileptic drugs, pharmacogenetics ofantiepileptic drugs, pharmacoresistant epilepsy, single nucleotidepolymorphism and antiepileptic drugs. We will also present our data onthe influence of several variants on the efficacy of carbamazepine[(SCN1A IVS5N + 5 GA; ABCB1 3435C T; EPHX1c (416 A G); EPHX1c(337 T C)] and valproic acid [(UGT1A6*2,c.541A>G, CYP2C9*2 (430C T), CYP2C9*3 (1075A C), CYP2C19*3, 636G>A, CYP2C19*2, 681G>A)for VPA] obtained in the past several years on patients treated at theClinic for Neurology, Faculty of Medicine, Skopje.referencesLoscher W et al. The clinical impact of pharmacogenetics on the treatment ofepilepsy. Epilepsia 2009 Jan;50(1):1-23. Epub 2008 Jul 8.Szoeke CE et al. Update on pharmacogenetics in epilepsy: a brief review. LancetNeurol. 2006 Feb;5(2):189-96.Tate SK et al. Genetic predictors of the maximum doses patients receive duringclinical use of antiepileptic drugs carbamazepine and phenytoin. Proc. Natl.Acad.Sci. USA 2005Apr 12;102(15);5507-12.Tan L et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9polymorphisms on the plasma concentrations of valproic acid in epileptic patients.Clin Neurol Neurosurg. 2010 May;112(4):320-3. Epub 2010 Jan 20.325fIfth congress of pharmacy of macedonIa WIth InternatIonal partIcIpatIonMacedonian Pharmaceutical Bulletin 57 (suppl), 2011CLINICAL PHARMACY oral presentationsINDIVIDUAlIzATsIJA NA TERAPIJASO carbamazepIne I valproIc acIdSterjev.Z, Dimovski A.J., Shuturkova. LjFarmatsevtski fakultet - Skopje, Univerzitet Sv. Kiril iMetodij-Skopje, R.MakedonijaEpilepsijata pretstavuva seriozno khronichno nevroloshko zabolu-vanje od koe shto vo svetot boleduvaat okolu 42 milioni lugje iliokolu 5% od tselokupnata svetska populatsija. Za tretman na ova za-boluvanje denes se koristat okolu 15 antiepileptichni lekovi (AEL)koi pripagjaat na razlichni khemiski grupi. Neuspekhot od postignuva-njeto na pozitiven terapevtski odgovor pri tretman na epilepsija-ta (farmakorezistentna epilepsija) se objasnuva kako sklop napovekje faktori povrzani so farmakokinetskite, farmakodina-mskite i farmakogenetskite osobini na antiepileptichnite lekovikoi vlijaat na rezultatot od terapijata. Prichinite za razlichniotodgovor na antiepileptichnata terapija se razlichni i vo sebe vklu-chuvaat: individualni razliki pomegju patsientite vo protsesot naapsorbtsija, metabolizam na AEL, varijabilnosti vo vrzuvanjeto naAEL za retseptornite mesta, varijatsii vo kolichestvoto na AEL re-tseptori produtsirani kaj razlichni individui i dr. Kako pozadinana site ovie razliki pomegju individuite stoi razlichniot genetskiprofil na sekoj poedinets. Se smeta deka postoi t.n genetska kon-trola vo sekoja faza niz koja pominuva lekot, od apsorptsijata pase do eleminatsija od organizmot. Do denes, vrsheni se ispituvanjana potentsijalno odgovorni geni koi kodiraat protsesi koi se di-rektno povrzani so terapevtskiot odgovor na lekovite Carbamazepinei Valproic acid i toa: genite vklucheni vo transportot na lekovite(MDR1/ABCB1), krajnite organ-lek retseptori (SCN1A) i geni vklu-cheni vo metabolnite protsesi (PXR, OCT2N, CYP2D6, CYP1A2,CYP2A6, CYP2B6, CYP2E1, UGT1A6, UGT1A9, UGT2B7). Za del odovie geni sprovedeni se soodvetni ispituvanja i vo R.Makedonija.Pri toa ispituvano e vlijanieto na polimorfizmite na genite vrzpojavata na zaboluvanjeto, terapevtskiot iskhod, dozata koja e po-trebna za da se postigne regulirana epilepsija, kontsentratsijatana lekot vo soodveten bioloshki materijal i pojavata na nesakaniefekti od terapijata. Glavna tsel na ovoj trud e prezentatsija na do-segashnite objaveni svetski podatotsi za vlijanieto na farmakoge-netikata vrz uspekhot na terapijata so AEL i prezentatsija na do-segashnite rezultati na toa pole vo R.Makedonija. Za realizianjena ovaa tsel napraven e pregled na dostapnata literatura na PubMed za periodot 1990-2011 godina. Kluchni zborovi koristeni priprebaruvanjeto se: antiepileptic drugs, pharmacogenetics of antiepilepticdrugs, pharmacoresistant epilepsy, single nucleotide polymorphismand antiepileptic drugs. Dobienite podatotsi od izvrshenoto preba-ruvanje se dopolneti so dobienite rezultati od dosegashnite is-pituvanja koi se realiziraat vo ramkite na zaednichka nauchno-istrazhuvachka rabota pomegju Farmatsevtskiot fakultet-Skopje iUniverzitetskata Klinikata za nevrologija, Meditsinski fakultet- Skopje. Dobienite podatotsi i rezultati se odnesuvaat na vlija-nieto na polimorfizmi na geni vrz rezultatot od terapijata i toa za:Carbamazepine (SCN1A IVS5N + 5 G-A; ABCB1 3435C-T; EPHX1c(416 A-G); EPHX1c (337 T-C))Valproic acid (UGT1A6*2,c.541A>G, CYP2C9*2 (430 C-T), CYP2C9*3(1075A-C), CYP2C19*3, 636G>A, CYP2C19*2, 681G>A)lITERATURALoscher W et al. The clinical impact of pharmacogenetics on the treatment ofepilepsy. Epilepsia 2009 Jan;50(1):1-23. Epub 2008 Jul 8.Szoeke CE et al. Update on pharmacogenetics in epilepsy: a brief review. LancetNeurol. 2006 Feb;5(2):189-96.Tate SK et al. Genetic predictors of the maximum doses patients receive duringclinical use of antiepileptic drugs carbamazepine and phenytoin. Proc. Natl.Acad.Sci. USA 2005Apr 12;102(15);5507-12.Tan L et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9polymorphisms on the plasma concentrations of valproic acid in epileptic patients.Clin Neurol Neurosurg. 2010 May;112(4):320-3. Epub 2010 Jan 20.326PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011KLINIChKA FARMATsIJA oralni prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOKLINIChKA FARMATsIJAposter prezentatsiiCLINICAL PHARMACYposter presentationsPotential drug-drug interactionsin Patients hosPitalized in theinfectious diseases hosPital'Mother teresa' in tiranaKlejda Hudhra1, Besnik Jucja2, Gjergji Minga1,Vigan Saliasi11Universiteti Amerikan i Tiranes, Fakulteti Mjekesor2Universiteti i Tiranes, Fakulteti i Mjekesise, Departamentii Farmacise 'Pirro Goda'introductionDrug-drug interactions constitute one of the potential mechanismsleading to often preventable adverse drug events and health damage.The purpose of this study is to evaluate the profile of potential drug-drug interactions in hospitalized patients in the Infectious Hospital"Mother Teresa", since there are no previous studies on this issue inAlbania.Material and Methods201medical files were examined and were excluded those with only onedrug. The selected medical files (patients) were investigated during thehospitalization period. Their prescriptions were analyzed once a week.Only gender, year of birth of patients, and drugs prescribed in the hospitalfiles, were recorded. The analysis of potential drug-drug interactions(pDDIs) among prescribed drugs was performed through the ThompsonMicromedex(r)1.0 program. Calculation of sums, frequencies and ratioswere calculated using Microsoft Excel and StatPlus 2009.resultsOf all patients included in the study, 31.46% (56) experienced at leastone pDDI. The mean number of pDDIs in files was 1.75 (range 1-6), SD1.19. In most of the files only one interaction was found (35 files). Outof 98 identified pDDIs, most were of moderate and minor severity(65.66% and 16.17%, respectively) and their documentation was mainlygood (51.52%) and fair (28.29%). Most frequently involved in potentialDDIswere nonsteroidal anti-inflammatory drugs (24.5%), fluoroquinolones(22.4%), and aminoglucosides (14.3%).conclusionThe presence of drug interactions is a permanent risk in hospitals, asthis study shows. The possibility of interactions was higher in patientstaking medication for chronic diseases such as hypertension, diabetesetc. concurrently with medications for the infectious disease thatcaused hospitalization. The high frequency of pDDIs should be a concernfor Albanian physicians, other health care professionists and patients.This way, the utilization of computer programs, pharmacotherapymonitoring of patients, further divulgation and awareness to preventharmful or clinically important drug-drug interactions and the phar-macist presence in the multidisciplinary team are some manners ofcontributing to hospitalized patients treatment. In the context of theevolving role of pharmacists, they should become an important factorin preventing and managing drug-drug interactions, especially in hos-pitalized patients.references1 Drug Interactions (page 1392) Daniel A. Hussar. Clinical Evaluation of Drugs,Encyclopedia of PHARMACEUTICAL TECHNOLOGY, Third Edition, VOLUME 1, editedby James Swarbrick, 2007 by Informa Healthcare USA2 Juurlink D.N., Mamdani M., Kopp A., Laupacis A., Redelmeier D.A. (2003) Drug-druginteractions among elderly patients hospitalized for drug toxicity. Journal of theAmerican Medical Association 289: 1652-1658.3 Bagheri H., Michel F., Lapeyre-Mestre M., Lagier E., Cambus J.P., Valdiguie P.,Montastruc J.L. (2000) Detection and incidence of drug-induced liver injuries inhospital: a prospective analysis from laboratory signals. British journal of clinicalpharmacology 50: 479-484.10 Angela D.M., KashubaS.B., Joseph S.B. (2005) Drug Interactions in Infectious Dis-eases 13-39 Mechanisms of Drug Interactions I Absorption, Metabolism and Excretion.11 Goodman and Gilman's The pharmacological basis of Therapeutics, Chapter 5. TheScience of Drug Therapy.6 Raschetti R., Morgutti M., Menniti-Ippolito F., Belisari A., Rossignoli A., Longhini P.,La Guidara C. (1999) Suspected adverse drug events requiring emergency departmentvisits or hospital admissions. European journal of clinical pharmacology 54: 959-963.7 Budnitz D.S., Pollock D.A., Weidenbach K.N., Mendelsohn A.B., Schroeder T.J., AnnestJ.L. (2006) National surveillance of emergency department visits for outpatientadverse drug events.Journal of the American Medical Association 296: 1858-1866.9 Katzung Basic & Clinical Pharmacology, tenth edition, 2007, McGraw-Hill, ISBN 978-88-299-1967-1973, page 111410 Atkinson J.A. Principles of clinical pharmacology second edition (2007), page 243,ISBN 13; 978-0-12-369417-111 Martinbiancho J., Zuckermann J., Dos Santos L., Silva M.M. (2007) Profile of druginteractions in hospitalized children. Pharmacy Practice 5: 157-161.12Micromedex(r)the iMPact of antineoPlasticdrugs on the health of healthcareProfessionalsVigan Saliasi1, Gjergji Minga1, Dhurata Tarifa2,Klejda Hudhra1, Delina Hudhra11Universiteti Amerikan i Tiranes, Fakulteti Mjekesor2Qendra Spitalore Universitare 'Nene Tereza', Sherbimi OnkologjikintroductionThe purpose of this study is to raise the awareness of medical staffworking at the premises of the Oncological Services at the UniversityHospital Centre "Mother Teresa" with the risk of contamination withcytotoxic substances during their manipulation, and their knowledgeof the Albanian legislation of Health Safety while exercising theirprofession.Material and MethodsWe analyzed Albanian legislation for the protection of employees whomanipulate hazardous substances which cause severe health damage,especially among those who work with cytotoxic substances(antineoplastic drugs). The study was conducted through aquestionnaire which was attended by employees of the OncologicalService at the University Hospital Centre "Mother Teresa" (physicians,pharmacists, nurses, cleaners) who were previously introduced to thequestionnaire.resultsThe review of the questionnaire showed that there are significantproblems in terms of law enforcement and other legal acts in theprotection of medical personnel from exposure to cytotoxic drugsduring the exercise of their profession. Absence or ignorance of thelegislation pointed out very clearly from the answers of the staff thatare very different, an indication that the recognition of regulatory acts.328PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011KLINIChKA FARMATsIJA poster prezentatsiiconclusionMOLSAEO specialists and those of the Ministry of Health must de-velop laws to ensure their protection from exposure to cytotoxic sub-stances by approximating them with European legislation, to providewith biological safety cabinets the equipments of pavilions of this serv-ice, to determine the contamination degree of premises and staff ofthis service by cytotoxic subjects.references1. Barbara Valanis, Dr, PhD, William Mr.Vollmer, Phd, Paul Steele, MPH, Occupationalexposure to antineoplastic agents self-reported miscarriages and stillbirths amondnurses and pharmacists: Journal of Occupational &Environmental Medicine vol.41,nr.8, 19902. Cytotoxic drugs and related waste: Safe handling in NSW Public Health System,2008 p.4-63. CDC (Center for Disease Control and Prevention) & NIOSH (The National Institutefor Occupational Safety medicine and Health) on line source, CDC.gov4. Susan Martin, RN, DNSc, AOCN: The adverse health effects of occupationalesposure to hazardous drugs. In Community Oncology, September/October 2005 vol2 nr.5 review article5. OSHA (occupational safety & Health Administration: on line www.OSHA.gov.OSHATechnical Manual page 1-306. Occupational Safety and Health Services, Department of Labour; New Zealand:Guidelines for the Safe handling of Cytotoxic Drugs and Related Waste, 19977.